Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.
Kataoka K, Mori K, Nakamura Y, Watanabe J, Akazawa N, Hirata K, Yokota M, Kato K, Kotaka M, Yamazaki K, Kagawa Y, Mishima S, Ando K, Miyo M, Yukami H, Laliotis G, Sharma S, Palsuledesai CC, Rabinowitz M, Jurdi A, Liu MC, Aleshin A, Kotani D, Bando H, Taniguchi H, Takemasa I, Kato T, Yoshino T, Oki E. Kataoka K, et al. Among authors: yukami h. Ann Oncol. 2024 Sep 16:S0923-7534(24)03763-3. doi: 10.1016/j.annonc.2024.08.2240. Online ahead of print. Ann Oncol. 2024. PMID: 39293512
ctDNA-based molecular residual disease and survival in resectable colorectal cancer.
Nakamura Y, Watanabe J, Akazawa N, Hirata K, Kataoka K, Yokota M, Kato K, Kotaka M, Kagawa Y, Yeh KH, Mishima S, Yukami H, Ando K, Miyo M, Misumi T, Yamazaki K, Ebi H, Okita K, Hamabe A, Sokuoka H, Kobayashi S, Laliotis G, Aushev VN, Sharma S, Jurdi A, Liu MC, Aleshin A, Rabinowitz M, Bando H, Taniguchi H, Takemasa I, Kato T, Kotani D, Mori M, Yoshino T, Oki E. Nakamura Y, et al. Among authors: yukami h. Nat Med. 2024 Sep 16. doi: 10.1038/s41591-024-03254-6. Online ahead of print. Nat Med. 2024. PMID: 39284954
Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study.
Yamamoto Y, Yukami H, Yamaguchi T, Ohori H, Nagasu S, Kagawa Y, Sugimoto N, Sonoda H, Yamazaki K, Takashima A, Okuyama H, Hasegawa H, Kondo C, Baba E, Matsumoto T, Kawamoto Y, Kataoka M, Shindo Y, Ishikawa T, Esaki T, Kito Y, Sato T, Funakoshi T, Yamaguchi T, Shimada Y, Moriwaki T. Yamamoto Y, et al. Among authors: yukami h. Int J Clin Oncol. 2024 Aug 28. doi: 10.1007/s10147-024-02613-0. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39196470
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.
Morinaga T, Inozume T, Kawazu M, Ueda Y, Sax N, Yamashita K, Kawashima S, Nagasaki J, Ueno T, Lin J, Ohara Y, Kuwata T, Yukami H, Kawazoe A, Shitara K, Honobe-Tabuchi A, Ohnuma T, Kawamura T, Umeda Y, Kawahara Y, Nakamura Y, Kiniwa Y, Morita A, Ichihara E, Kiura K, Enokida T, Tahara M, Hasegawa Y, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Morinaga T, et al. Among authors: yukami h. Cancer Res Commun. 2022 Jul 28;2(7):739-753. doi: 10.1158/2767-9764.CRC-22-0050. eCollection 2022 Jul. Cancer Res Commun. 2022. PMID: 36923281 Free PMC article.
Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer.
Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, Hirata K, Akazawa N, Kataoka K, Sharma S, Aushev VN, Aleshin A, Misumi T, Taniguchi H, Takemasa I, Kato T, Mori M, Yoshino T. Kotani D, et al. Among authors: yukami h. Nat Med. 2023 Jan;29(1):127-134. doi: 10.1038/s41591-022-02115-4. Epub 2023 Jan 16. Nat Med. 2023. PMID: 36646802 Free PMC article.
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum.
Ito T, Takashima A, Yamazaki K, Yukami H, Uetake H, Tsuda M, Suto T, Moriwaki T, Sugimoto N, Ojima H, Takii Y, Yasui H, Esaki T, Tsuji A, Goto M, Saruta M, Otsu S, Shinozaki K, Fujiwara T, Tamura T, Baba E, Shiozawa M, Denda T, Ueno H, Nagashima K, Shimada Y. Ito T, et al. Among authors: yukami h. Int J Clin Oncol. 2022 Sep;27(9):1450-1458. doi: 10.1007/s10147-022-02208-7. Epub 2022 Jul 21. Int J Clin Oncol. 2022. PMID: 35861943
Definitive chemoradiotherapy has comparable survival outcomes to esophagectomy in patients with clinical T1N0M0 esophageal squamous cell carcinoma: real-world data.
Sawada K, Kotani D, Yukami H, Mishima S, Fujiwara H, Kadota T, Nakajo K, Yoda Y, Nakamura M, Hojo H, Yano T, Fujita T, Kojima T. Sawada K, et al. Among authors: yukami h. Int J Clin Oncol. 2022 Aug;27(8):1279-1288. doi: 10.1007/s10147-022-02185-x. Epub 2022 Jul 2. Int J Clin Oncol. 2022. PMID: 35779118
Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials.
Yukami H, Kawazoe A, Lin YT, Koyama S, Fukuoka S, Hara H, Takahashi N, Kojima T, Asayama M, Yoshii T, Bando H, Kotani D, Nakamura Y, Kuboki Y, Mishima S, Wakabayashi M, Kuwata T, Goto M, Higuchi K, Yoshino T, Doi T, Nishikawa H, Shitara K. Yukami H, et al. Clin Cancer Res. 2022 Aug 15;28(16):3480-3488. doi: 10.1158/1078-0432.CCR-22-0630. Clin Cancer Res. 2022. PMID: 35679062 Free PMC article.
[Support for a balance between work schedules and treatment regimens among workers with illness: A questionnaire survey focusing on company size in Wakayama Prefecture, Japan].
Morioka I, Terashita H, Miyashita K, Ikuta Z, Takeshita T, Fujiyoshi A, Yamamoto N, Yukami H. Morioka I, et al. Among authors: yukami h. Sangyo Eiseigaku Zasshi. 2023 Jan 25;65(1):28-40. doi: 10.1539/sangyoeisei.2021-051-E. Epub 2022 Mar 19. Sangyo Eiseigaku Zasshi. 2023. PMID: 35314568 Free article. Japanese.
17 results